Verition Fund Management
DYN icon

Verition Fund Management’s Dyne Therapeutics DYN Stock Holding History

Verition Fund Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,453
Closed -$204K – 2628
2025
Q4 		$204K Buy
+10,453
New +$198K ﹤0.01% 3169
2025
Q3 		– Sell
-35,923
Closed -$342K – 3812
2025
Q2 		$342K Buy
35,923
+23,181
+182% +$255K ﹤0.01% 3140
2025
Q1 		$133K Sell
12,742
-9,960
-44% -$142K ﹤0.01% 3130
2024
Q4 		$535K Buy
+22,702
New +$672K ﹤0.01% 2442

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Verition Fund Management's DYN Position: Q1 2026 in Review

Verition Fund Management sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 10,453 shares — an estimated $204K sold.

Verition Fund Management first reported a position in DYN in Q4 2024 and held it in 4 quarters. The position peaked at $535K in Q4 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Verition Fund Management reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 10,453 Dyne Therapeutics shares in Q1 2026, an estimated $204K.
  • Verition Fund Management first reported a position in Dyne Therapeutics in Q4 2024 and held it in 4 quarters.
  • Verition Fund Management's Dyne Therapeutics position peaked at $535K in Q4 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.